Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label extension study of PRM-151 in idiopathic pulmonary fibrosis
jRCT2001210001Phase 3Completed
- Sponsor
- Roche
- Start
- Jan 2022
- Modality
- Recombinant Proteins and Enzymes
01
Overview
Phase 3, open-label trial of zinpentraxin alfa in idiopathic pulmonary fibrosis (IPF) (2 cohorts), sponsored by Roche. Primary endpoints: Percentage of participants with adverse events, Percentage of participants with infusion-related reactions and other adverse events of special interest and 2 more. Started Jan 2022; status: completed.
02
Drugs
zinpentraxin alfa
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on jRCT2001210001.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2001210001.